

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/27, 31/66, 31/44, 31/445, 31/40, 31/645, 31/435, 31/55		A1	(11) International Publication Number: WO 99/07359
			(43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/GB98/02378 (22) International Filing Date: 7 August 1998 (07.08.98) (30) Priority Data: 9716879.3 8 August 1997 (08.08.97) GB (71) Applicant (for all designated States except US): SHIRE INTERNATIONAL LICENSING B.V. [NL/NL]; Frederiksplein 42, NL-1017 XN Amsterdam (NL). (71)(72) Applicant and Inventor: SNORRASON, Ernir [IS/IS]; Stigahlid 80, IS-105 Reykjavik (IS). (72) Inventor; and (75) Inventor/Applicant (for US only): MURRAY, James, Robert [GB/GB]; Lamb House, Ludwell, Shaftesbury, Dorset SP7 9ND (GB). (74) Agents: GRANT, Anne, Rosemary et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: USE OF CHOLINESTERASE INHIBITORS FOR TREATING ATTENTION DEFICIT DISORDERS			
(57) Abstract The invention provides the use of cholinesterase inhibitors, particularly acetylcholinesterase inhibitors such as galantamine, in the manufacture of a medicament for combatting attention deficit disorders.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	RS	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF CHOLINESTERASE INHIBITORS FOR TREATING ATTENTION DEFICIT DISORDERS

5 The present invention relates to a method of
combatting attention deficit disorders (hereinafter
referred to as ADD). In particular, the invention
relates to the use of a pharmaceutically acceptable
cholinesterase inhibitor in the manufacture of a
10 medicament for use in combatting ADD.

 Attention deficit disorders affect children,
adolescents and adults affecting up to 10% of children
and at least 2% of adults. The childhood condition is
often known as attention-deficit hyperactivity disorder
15 (ADHD). Symptoms usually first manifest between the
ages of 2 - 5. These children have a short attention
span, motor hyperactivity, and are disorganised,
forgetful and impulsive. ADHD can have a serious effect
on the child's academic progress and performance and
20 causes stress to family and teachers and difficulties in
interacting with the child's peer group. The condition
can persist into adult life. In adults, the major
symptoms include distractibility, disorganisation and
accident proneness. The condition in adults and
25 children causes serious disruption to normal lifestyle
patterns, and creates great stresses to all aspects of
daily life, in the home, the workplace and in social
situations. ADD as used herein covers both the adult
and child forms of the condition, as well as
30 hyperkinetic disorders and disorders which include any
of the characterising criteria of the American
Psychiatric Association's DSM-IV Classification of the
disorders.

 Various therapies have been proposed but have not
35 proved satisfactory, due *inter alia* to lack of efficacy
and/or undesirable side effects. Stimulants such as
dexamphetamine, methylphenidate and pemoline have been

- 2 -

used clinically in the management of ADD. Whilst they have been found to improve the primary manifestations such as motor activity, distractability and impulsivity in some sufferers, their side effects including anorexia, delayed onset of sleep, mood changes and exacerbation of pre-existing psychotic symptoms together with the possible potential for abuse, limits their utility. Other classes of drug such as tricyclic antidepressants have been suggested in the literature but are not generally regarded as being effective agents for the management of ADD. There is accordingly a need for a new therapeutic method for the management of ADD. The present invention provides such a method.

Thus we have surprisingly found that cholinesterase inhibitors such as galantamine can effectively combat ADD.

According to one aspect, the present invention provides a method of combatting ADD comprising administering to a subject a pharmaceutically acceptable cholinesterase inhibitor.

According to a related aspect, the invention provides the use of a pharmaceutically acceptable cholinesterase inhibitor in the manufacture of a medicament for combatting ADD.

As used herein the term 'combatting' includes both therapy and prophylaxis.

The invention encompasses the use of any cholinesterase inhibitor, provided of course that it is pharmaceutically acceptable.

Examples of cholinesterase inhibitors which may be used according to the invention include, but are not limited to, physostigmine, tacrine and tacrine analogues, fasciculin, metrifonate, heptyl-physostigmine, norpyridostigmine, norneostigmine, huperazine, donepezil and pro-drugs of any of these in which the inhibitor is modified in accordance with principles of pro-drug construction known in the art. Examples of such


- 3 -

modifications include the introduction of hydrophilic or lipophilic groups to enhance solubility, or penetration through cell membranes, respectively.

Preferred cholinesterase inhibitors for use according to the invention are acetylcholinesterase inhibitors, particularly those which are capable of crossing the blood brain barrier.

Particularly preferred cholinesterase inhibitors for use according to the invention include galantamine, epigalantamine and norgalantamine, and analogues, salts and derivatives of any of these. Galantamine was previously known as galanthamine. It is a tertiary alkaloid which can be extracted from various snowdrop bulbs e.g. the Caucasian snowdrop *galanthus woronowii* (Amaryllidaceae) and related species and daffodil bulbs or made by chemical synthesis. It has a high selectivity for acetylcholinesterase as opposed to butyrylcholinesterase. It is active substantially selectively at nicotinic receptor sites with substantially little effect on muscarinic receptor sites.

Particularly preferred cholinesterase inhibitors for use in the invention are galantamine and its derivatives of formula (I):



wherein the broken line represents an optionally present double bond between carbon atoms 3 and 4, each R₁ is

- 4 -

independently selected from hydrogen, hydroxyl, straight or branched chain alkyl, hydroxyalkyl, carboxyalkyl amino, alkylamino, acyl, lower alkanoyl, cyano, sulfhydryl, C₁₋₆alkoxy, alkylthio, aryloxy, arylthio, R₃-substituted aryloxy, R₃-substituted arylthio, aralkoxy, an optionally R₃-substituted aliphatic or aryl carbamyl group, aralkylthio, R₃-substituted aralkoxy, R₃-substituted aralkylthio, aryloxymethyl, R₃-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R₃-substituted benzoyloxy, aryloxycarbonyl and R₃-substituted aryloxycarbonyl,

R₂ is selected from hydrogen, straight or branched chain C₁₋₆alkyl, alkenyl or alkaryl group, optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroaryl-alkyl, aryl, arylalkyl, cyano, amyl, aroyl, cycloalkylmethyl, allyl, phenyl, R₃-substituted phenyl, alkylphenyl, R₃-substituted alkylphenyl, heterocyclyl selected from α - or β -furyl, α - or β -thienyl, thenyl, pyridyl, pyrazinyl, and pyrimidyl, alkyl-heterocyclyl or R'-substituted heterocyclyl, where R' is alkyl or alkoxy,

each R₃ is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, hydroxyalkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, thiaryloxy, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkaryl amino, fluoro, chloro, bromo, iodo, and trifluoromethyl,

each R₄ is independently selected from hydrogen, halo, trifluoromethyl or C₁₋₄-alkyl,

each R₅ is independently selected from hydrogen or hydroxymethyl,

R₆ is hydrogen or C₁₋₆alkyl, or when R₁ at carbon atom 2 is hydroxyl, R₆ may be a moiety of formula I wherein R₆ is hydrogen and R₁ is a linking bond; or

R₁ at carbon atom 2 and R₆ may jointly form semicarbazone,

- 5 -


X is oxygen or NR_3 ,

Y is nitrogen or phosphorus,

and methylenedioxy derivatives thereof and pharmaceutically acceptable acid addition salts thereof.

5 Of the compounds of formula I which may be used in the method of the invention, preferred compounds are those in which the alkyl moieties contain 1 to 8 carbon atoms, halogen atoms are preferably fluorine, bromine, chlorine, aryl moieties are preferably phenyl, 10 cycloalkyl groups are preferably 3- to 7-membered rings, especially cyclopropyl or cyclobutyl, acyl groups are preferably lower alkanoyl groups and heteroaryl moieties are preferably 5- to 8-membered rings, e.g., thienyl, furyl, pyridyl, pyrrolyl, or pyrizanyl.

15 Preferred compounds of formula I are the compounds of formula II



II

wherein R^1 and R^2 which may be the same or different each represents a hydrogen atom or an acyl group, such 30 as a lower alkanoyl group, e.g. an acetyl group or a straight-chained or branched alkyl group, e.g. methyl, ethyl, propyl, or isopropyl;

R^3 is a straight or branched chain alkyl, alkenyl or alkaryl group which is optionally substituted by a 35 halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroarylalkyl, aroyl, aroylalkyl or cyano group; and

- 6 -

R⁴ represents a hydrogen or a halogen atom attached to at least one of the ring carbons of the tetracyclic skeleton,

and pharmaceutically acceptable salts thereof, such as a hydrobromide, hydrochloride, methylsulphate or methiodide.

Formula II includes galantamine itself.

Particularly preferred is galantamine itself, and salts thereof such as halides for example galantamine hydrobromide and the use of these compounds in the manufacture of a medicament for combatting ADD provides a further aspect of the invention.

Among these compounds are those described in EP-A-236684 and WO88/08708, the disclosures of which are incorporated herein by reference. Galantamine and its derivatives of formula I and II may be prepared by the methods described in these publications.

The cholinesterase inhibitors for use in the invention include compounds which are functionally similar to galantamine. These are defined herein as compounds which possess an at least 10-fold selectivity, preferably an at least 20-fold selectivity, more preferably an at least 40-fold selectivity, and most preferably an at least 50 fold selectivity, for acetylcholinesterase as opposed to butyrylcholinesterase, when measured by the in vitro method of Thomsen and Kewitz: Selective Inhibition of Human Acetylcholinesterase by Galantamine in vitro and in vivo, Life Sciences, Vol 46, pp. 1553-1558 (1990), and T. Thomsen, H. Kewitz and O. Pleul, J. Clin. Chem. Clin. Biochem. 26 469-475 (1988). The in vitro test described by Thomsen and Kewitz in Life Sciences, Vol 46, pp 1553-1558 (1990) is the one referred to herein whenever numeric (10-fold, 20-fold, 40-fold) reference to selectivity for acetylcholinesterase as opposed to butyrylcholinesterase is made. According to Thomsen and Kewitz, galantamine hydrobromide, when tested under the

- 7 -

conditions described, shows a 50-fold selectivity; this selectivity value is taken as the "fix-point" whenever in vitro selectivities are discussed herein and could be used, for the purpose of determining the selectivities for other cholinesterase inhibitors, as a calibration value which is the one to establish with galantamine hydrobromide in any repetition of the experiment described by Thomsen and Kewitz. Thus, with reference to this determination method, a preferred acetylcholinesterase inhibitor is one which in the in vitro method described has an at least 10-fold selectivity for acetylcholinesterase as opposed to butyrylcholinesterase, such as an at least 20-fold selectivity for acetylcholinesterase as opposed to butyrylcholinesterase, e.g. an at least 40-fold selectivity for acetylcholinesterase as opposed to butyrylcholinesterase. A selectivity test is commercially available (from Sigma Diagnostics).

For use in the method of the invention the cholinesterase inhibitor such as galantamine and derivatives and salts thereof may be formulated according to conventional methods of pharmacy, together where appropriate with one or more pharmaceutically acceptable carriers, excipients or diluents such as, for example, are described in Remingtons Pharmaceutical Sciences. Such formulations may for example take the form of tablets, capsules, solutions, or lozenges, pessaries, creams, suppositories or transdermal formulations such as patches, creams, ointments or lotions, depending upon the administration route to be used, which may include enterally or parenterally, including orally or injection via the intravenous, intramuscular or subcutaneous routes, or intrathecally by means of an implanted device.

Oral and transdermal administration routes are preferred.

Precise dosage rates and regimes will depend upon

- 8 -

the individual patient and may be determined by the medical practitioner based on individual circumstances. For oral administration doses may be within the range of 5-100 mg per day, such as 2 to 70 mg per day eg. 10 to 30 mg. For transdermal administration galanthamine may be delivered in equivalent daily doses. For parenteral administration, dosages may be in the range of 0.1 to 100 mg per day, such as 5 to 100 mg per day, e.g. 10 to 50 mg per day, including 5 to 30 mg per day; lower dosages are often preferred.

Galantamine and its acid addition salts form crystals. They are generally only sparingly soluble in water at room temperature; therefore, injectable compositions are normally in the form of an aqueous suspension. If necessary, pharmaceutically-acceptable suspension aids may be employed. Typically, such a suspension will be employed at a concentration of 0.1-50 mg/ml, such as 1-50 mg/ml, more commonly 5-40 mg/ml, for example, 5-30 mg/ml or 10-40 mg/ml, such as 10-30 mg/ml, especially 20-30 mg/ml of galantamine.

Cholinesterase inhibitors such as galantamine and salts thereof may be used as the sole drug in the management of ADD, or may be used together with other agents useful in managing ADD.

The invention will now be described with reference to the following non-limiting examples.

- 9 -

Example 1Formulation of tablets containing galantamine5 Composition of 1 tablet containing 1 mg galantamine

	Galantamine hydrobromide	0.001 g
	Calcium phosphate	0.032 g
	Lactose	0.005 g
10	Wheat Starch	0.0056 g
	Microcrystalline Cellulose	0.015 g
	Talc	0.0007 g
	Magnesium Stearate	0.0007 g

15 Composition of 1 tablet containing 5 mg galantamine

	Galantamine hydrobromide	0.005 g
	Calcium phosphate	0.024 g
	Lactose	0.004 g
20	Wheat Starch	0.004 g
	Microcrystalline Cellulose	0.04 g
	Talc	0.002 g
	Magnesium Stearate	0.001 g

25 Composition of 1 tablet containing 10 mg galantamine

	Galantamine hydrobromide	0.010 g
	Lactose	0.040 g
	Wheat Starch	0.0234 g
30	Microcrystalline Cellulose	0.0374 g
	Talc	0.0036 g
	Magnesium Stearate	0.0012 g
	Gelatin	0.0044 g

35 Preparation

All the tablets are prepared according to routine
tableting procedures.

- 10 -

Example 2Treatment of patients suffering from ADD

Three patients aged 9 to 11 years diagnosed as having ADD were treated with 5 mg of galantamine given 3 times per day for a total of 14 days. After this period of time, the patients showed marked improvement of symptoms, particularly as regards attention and restlessness, as judged on an ecological behavioural scale (translated: Barkley, RA et al, Assessing situational variation in children's problem behaviours: The Home and School Situations Questionnaires, in RJ Prinz (Ed), Advances in Behavioural Assessment of Children and Families, vol 3, pp 157-176, Greenwich, CT, JAI Press, Inc).

A further cohort of two 5 year old patients with ADD have been treated and again symptoms have generally improved, especially attention, as measured by ANT (Amsterdam Neuropsychological Tests), which are standard tests that measure reaction times for different tasks.

The protocol in this case is first a baseline testing before medication and retesting after 2 days on medication and then after a week repeated testing. Ecological scales were also used before and are now being evaluated after one week after two weeks etc. for a treatment of one month duration. The following table shows a selection of results obtained for these two children before and after treatment with galantamine.

- 11 -

		Before:				After:			
		mean	Sd	miss ¹	Fa ²	mean	Sd	miss	Fa
Patient A									
5	Baseline:	685	766			727	470		
	GoNoGo	705	158	1	1	655	173	1	2
	Sustained Att.	1302	565	14	13	1222	472	4	6
	Focused Att.	1214	404			1352	434	0	
Patient B									
10	Baseline:	1051	899			780	418		
	GoNoGo	804	162	2	9	766	172	3	3
	Sustained Att.	1444	721	31	29	1152	600	20	50
	Focused Att.	2444	1367	1		1166	270	3	

15

¹ Missed task² Failed attempt


20 This data was normalized and submitted to error analysis that showed an improvement in attention (reduction in time (msec) to complete certain tasks and with fewer errors) over 2.5 standard deviations after medication with galantamine hydrobromide 2.5 mg 3 times a day.

CLAIMS

- 5 1. The use of a pharmaceutically acceptable cholinesterase inhibitor or a pro-drug therefor in the manufacture of a medicament for combatting attention deficit disorders.
- 10 2. The use is claimed in claim 1 wherein the disorder is attention deficit hyperactivity disorder.
3. The use as claimed in claim 1 wherein the disorder is a hyperkinetic disorder.
- 15 4. The use as claimed in any one of the preceding claims wherein the cholinesterase inhibitor is an acetyl cholinesterase inhibitor.
- 20 5. The use as claimed in any one of the preceding claims wherein the cholinesterase inhibitor is active substantially selectively at nicotinic receptor sites.
6. The use as claimed in any one of the preceding
- 25 claims wherein the cholinesterase inhibitor is capable of crossing the blood brain barrier.
7. The use as claimed in any one of claims 1 to 4 wherein the cholinesterase inhibitor is selected from
- 30 physostigmine, tacrine and tacrine analogues, fasciculin, metrifonate, heptyl-physostigmine, norpyridostigmine, norneostigmine, huperazine, donepezil and pro-drugs of any of these.
- 35 8. The use is claimed in any one of claims 1 to 6 wherein the cholinesterase inhibitor is selected from glantamine, epigalantamine and norgalantamine, and

analogues, salts and derivatives of any of these.

9. The use as claimed in any of the preceding claims wherein the cholinesterase inhibitor is selected from galantamine and its derivatives of formula (I):



wherein the broken line represents an optionally present double bond between carbon atoms 3 and 4, each R_1 is independently selected from hydrogen, hydroxyl, straight or branched chain alkyl, hydroxyalkyl, carboxyalkyl amino, alkylamino, acyl, lower alkanoyl, cyano, sulfhydryl, C_{1-6} alkoxy, alkylthio, aryloxy, arylthio, R_3 -substituted aryloxy, R_3 -substituted arylthio, aralkoxy, an optionally R_3 -substituted aliphatic or aryl carbamyl group, aralkylthio, R_3 -substituted aralkoxy, R_3 -substituted aralkylthio, aryloxymethyl, R_3 -substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R_3 -substituted benzoyloxy, aryloxycarbonyl and R_3 -substituted aryloxycarbonyl,

R_2 is selected from hydrogen, straight or branched chain C_{1-6} alkyl, alkenyl or alkaryl group, optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroaryl-alkyl, aryl, arylalkyl, cyano, amyl, aroyl, cycloalkylmethyl, allyl, phenyl, R_3 -substituted phenyl, alkylphenyl, R_3 -substituted alkylphenyl, heterocyclyl selected from α - or β -furyl, α - or β -thienyl, thenyl,

- 14 -

pyridyl, pyrazinyl, and pyrimidyl, alkyl-heterocyclyl or R'-substituted heterocyclyl, where R' is alkyl or alkoxy,

each R₃ is independently selected from hydrogen,
5 hydroxyl, sulfhydryl, alkyl, hydroxyalkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, thiaryloxy, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo, and trifluoromethyl,

10 each R₄ is independently selected from hydrogen, halo, trifluoromethyl or C₁₋₄-alkyl,

each R₅ is independently selected from hydrogen or hydroxymethyl,

R₆ is hydrogen or C₁₋₆alkyl, or when R₁ at carbon
15 atom 2 is hydroxyl, R₆ may be a moiety of formula I wherein R₆ is hydrogen and R₁ is a linking bond; or


R₁ at carbon atom 2 and R₆ may jointly form semicarbazone,

X is oxygen or NR₃,

20 Y is nitrogen or phosphorus,

and methylenedioxy derivatives thereof and pharmaceutically acceptable acid addition salts thereof.

10. The use as claimed in any one of the preceding
25 claims wherein the cholinesterase inhibitor is selected from compounds of formula II



wherein R¹ and R² which may be the same or different

- 15 -

each represents a hydrogen atom or an acyl group, such as a lower alkanoyl group, e.g. an acetyl group or a straight-chained or branched alkyl group, e.g. methyl, ethyl, propyl, or isopropyl;


5 R^3 is a straight or branched chain alkyl, alkenyl or alkaryl group which is optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroarylalkyl, aroyl, aroylalkyl or cyano group; and
 10 R^4 represents a hydrogen or a halogen atom attached to at least one of the ring carbons of the tetracyclic skeleton, and pharmaceutically acceptable salts thereof, such as a hydrobromide, hydrochloride, methylsulphate or methiodide.

15

11. The use according to any one of the preceding claims where the cholinesterase inhibitor is galantamine or a salt thereof.

20 12. The use of galantamine or a derivative thereof of formula I:

25



30

wherein the broken line represents an optionally present double bond between carbon atoms 3 and 4, each R_i is
 35 independently selected from hydrogen, hydroxyl, straight or branched chain alkyl, hydroxyalkyl, carboxyalkyl amino, alkylamino, acyl, lower alkanoyl, cyano,

- 16 -

sulfhydryl, C₁₋₆alkoxy, alkylthio, aryloxy, arylthio, R₃-substituted aryloxy, R₃-substituted arylthio, aralkoxy, an optionally R₃-substituted aliphatic or aryl carbamyl group, aralkylthio, R₃-substituted aralkoxy, R₃-substituted aralkylthio, aryloxymethyl, R₃-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R₃-substituted benzoyloxy, aryloxy-carbonyl and R₃-substituted aryloxy-carbonyl,

R₂ is selected from hydrogen, straight or branched chain C₁₋₆alkyl, alkenyl or alkaryl group, optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroaryl-alkyl, aryl, arylalkyl, cyano, amyl, aroyl, cycloalkylmethyl, allyl, phenyl, R₃-substituted phenyl, alkylphenyl, R₃-substituted alkylphenyl, heterocyclyl selected from α- or β-furyl, α- or β-thienyl, thenyl, pyridyl, pyrazinyl, and pyrimidyl, alkyl-heterocyclyl or R'-substituted heterocyclyl, where R' is alkyl or alkoxy,

each R₃ is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, hydroxyalkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, thiaryloxy, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-aryl-amino, N-alkaryl-amino, fluoro, chloro, bromo, iodo, and trifluoromethyl,

each R₄ is independently selected from hydrogen, halo, trifluoromethyl or C₁₋₄-alkyl,

each R₅ is independently selected from hydrogen or hydroxymethyl,

R₆ is hydrogen or C₁₋₆alkyl, or when R₁ at carbon atom 2 is hydroxyl, R₆ may be a moiety of formula I wherein R₆ is hydrogen and R₁ is a linking bond; or

R₁ at carbon atom 2 and R₆ may jointly form semicarbazone,

X is oxygen or NR₃,


Y is nitrogen or phosphorus,

and methylenedioxy derivatives thereof and

- 17 -

pharmaceutically acceptable acid addition salts thereof
in the manufacture of a medicament for combatting
attention deficit disorders.

- 5 13. The use of galantamine or a derivative thereof of
formula II



20 wherein R¹ and R² which may be the same or different
each represents a hydrogen atom or an acyl group, such
as a lower alkanoyl group, e.g. an acetyl group or a
straight-chained or branched alkyl group, e.g. methyl,
ethyl, propyl, or isopropyl;

25 R³ is a straight or branched chain alkyl, alkenyl or
alkaryl group which is optionally substituted by a
halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro,
amino, aminoalkyl, acylamino, heteroaryl,

30 heteroarylalkyl, aroyl, aroylalkyl or cyano group; and
R⁴ represents a hydrogen or a halogen atom attached
to at least one of the ring carbons of the tetracyclic
skeleton,

35 and pharmaceutically acceptable salts thereof, such
as a hydrobromide, hydrochloride, methylsulphate or
methiodide in the manufacture of a medicament for
combatting attention deficit disorders.

14. The use of galantamine or a salt thereof in the

- 18 -

manufacture of a medicament for combatting attention deficit disorders.

5 15. A method of combatting attention deficit disorders comprising administering a pharmaceutically acceptable cholinesterase inhibitor or a pro-drug therefor.

16. A method as claimed in claim 15 wherein the disorder is as defined in claim 2 or claim 3.

10

17. A method as claimed in claim 15 or claim 16 wherein the cholinesterase inhibitor is as defined in any one of claims 4 to 14.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02378

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/27 A61K31/66 A61K31/44 A61K31/445 A61K31/40
A61K31/645 A61K31/435 A61K31/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 98 39000 A (EISAI CO LTD ; ROGERS SHARON L (US)) 11 September 1998 see the whole document	1-7, 15-17
P, X	WO 97 46527 A (EISAI CO LTD) 11 December 1997 see abstract see page 27, last paragraph - page 28, last paragraph; claims 1, 79-87	1-7, 15-17
X	EP 0 515 302 A (SNORRASON ERNIR) 25 November 1992 see abstract	1, 4-6, 8-15, 17
Y	see page 15, line 22 - line 55; claims 1, 4, 8-21, 24	2, 3

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 December 1998

Date of mailing of the international search report

22/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02378

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	E.D. LEVIN ET AL.: "NICOTINE EFFECTS ON ADULTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER" PSYCHOPHARMACOLOGY, vol. 123, no. 1, 1996, pages 55-63, XP002087140 see the whole document	2,3
X	WO 92 20328 A (SNORRASON ERNIR) 26 November 1992 see abstract see claims 1,5,8-18,21-27	1-6,8-17
X	US 4 550 113 A (LAVRETSKAYA ELIONORA F ET AL) 29 October 1985 see abstract see column 5, line 52 - line 55 see column 7, line 43 - line 50; claims	1,4-6, 15,16
X	J.L. JUNCOS ET AL.: "CHOLINERGIC STRATEGIES IN TOURETTE SYNDROME: AN OPEN-LABEL TRIAL OF TACRINE HYDROCHLORIDE" NEUROLOGY, vol. 48, no. 3S.2, March 1997, page A397 XP002087141 see abstract S69.003	1-7, 15-17
X	B.J. SAHAKIAN ET AL.: "NICOTINE AND TETRAHYDROAMINOACRIDINE: EVIDENCE FOR IMPROVED ATTENTION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER TYPE" DRUG DEVELOPMENT RESEARCH, vol. 31, no. 1, 1994, pages 80-88, XP002087142 see abstract see page 82, left-hand column, last paragraph - page 86	1,2,4-7, 15-17
X	KIRKBY D L ET AL: "EFFECTS OF ANTICHOLINESTERASE DRUGS TACRINE AND 32020, THE 5-HT3 ANTAGONIST ONDANSETRON, AND THE H3 ANTAGONIST THIOPERAMIDE, IN MODELS OF COGNITION AND CHOLINERGIC FUNCTION" BEHAVIOURAL PHARMACOLOGY, vol. 7, no. 6, November 1996, pages 513-525, XP002068916 see the whole document	1,2,4-7, 15-17

-/--

INTERNATIONAL SEARCH REPORT

Inte: onal Application No

PCT/GB 98/02378

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J.L. MUIR ET AL.: "REVERSAL OF VISUAL ATTENTIONAL DYSFUNCTION FOLLOWING LESIONS OF THE CHOLINERGIC BASAL FOREBRAIN BY PHYSOSTIGMINE AND NICOTINE BUT NOT BY THE 5-HT ₃ RECEPTOR ANTAGONIST, ONDANSETRON" PSYCHOPHARMACOLOGY, vol. 118, no. 1, 1995, pages 82-92, XP002087143 see the whole document	1,2,4-7, 15-17
X	D.N.C. JONES ET AL.: "AGE-ASSOCIATED IMPAIRMENTS IN A TEST OF ATTENTION: EVIDENCE FOR INVOLVEMENT OF CHOLINERGIC SYSTEMS" JOURNAL OF NEUROSCIENCE, vol. 15, no. 11, 1995, pages 7282-7292, XP002087144 see the whole document	1,2,4-7, 15-17
X	C. KERTZMAN ET AL.: "EFFECTS OF PHYSOSTIGMINE ON SPATIAL ATTENTION IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY" ARCHIVES OF NEUROLOGY, vol. 47, no. 12, 1990, pages 1346-1350, XP002087145 see the whole document	1,2,4-7, 15-17
X	RILEY E P ET AL: "THE EFFECTS OF PHYSOSTIGMINE ON OPEN-FIELD BEHAVIOR IN RATS EXPOSED TO ALCOHOL PRENATALLY" ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, vol. 10, no. 1, January 1986, pages 50-53, XP000612593 see abstract	1,2,4-7, 15-17
X	WO 95 29909 A (PFIZER ;VOLKMANN ROBERT A (US); JASYS VYTAUTAS J (US); BRIGHT GENE) 9 November 1995 see abstract see page 9, line 3 - page 10, line 3; claims 45,46	1,2,4-7, 15-17
X	EP 0 229 391 A (EISAI CO LTD) 22 July 1987 see abstract see page 12, line 18 - page 13, line 1 see page 15, line 7 - line 11 see page 49, line 10 - line 27; table 3	1,2,4-6, 15-17

-/--

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/GB 98/02378

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 411 534 A (WARNER LAMBERT CO) 6 February 1991 see abstract see page 2, line 1 - line 12 see page 3, line 1 - line 43; claims 1,5 ---	1,3-7, 15-17
X	EP 0 607 864 A (TAKEDA CHEMICAL INDUSTRIES LTD) 27 July 1994 see abstract see page 71, line 35 - line 50 see page 116, line 25 - line 35; table 76 see claims 28-34 ---	1,3-6, 15-17
X	EP 0 193 926 A (YISSUM RES DEV CO) 10 September 1986 see abstract see page 1 - page 8; table 2 see page 25, paragraph 4; claims 1-3 -----	1,3-6, 15-17

INTERNATIONAL SEARCH REPORT

I. .national application No.

PCT/GB 98/ 02378

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15-17
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 15-17
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION SHEET PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ GB 98/02378

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

In view of the large number of compounds which are theoretically contained within the definition "cholinesterase inhibitor" of claims 1 and 15, the search had to be restricted on economic grounds to the general idea of the invention and to the compounds mentioned in claims 7-14 (Art. 6 PCT; Guidelines Part B, Chapt. II.7 last sentence and Chapter III, 3.7).

Claims searched completely: 7-14

Claims searched incompletely: 1-6, 15-17

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 98 02378

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

In view of the large number of compounds which are theoretically contained within the definition "cholinesterase inhibitor" of claims 1 and 15, the search had to be restricted on economic grounds to the general idea of the invention and to the compounds mentioned in claims 7-14 (Art. 6 PCT; Guidelines Part B, Chapt.II.7 last sentence and Chapt.III,3.7). Claims

searched completely: 7-14

Claims searched incompletely:

1-6,15-17

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02378

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9839000	A	11-09-1998	NONE	
WO 9746527	A	11-12-1997	AU 1153097 A AU 2979297 A WO 9746526 A JP 10053576 A	05-01-1998 05-01-1998 11-12-1997 24-02-1998
EP 0515302	A	25-11-1992	AU 663086 B AU 1873692 A AU 1886392 A CA 2062094 A CA 2103022 A WO 9220328 A EP 0584285 A EP 0879596 A JP 6507621 T NO 934103 A NZ 242743 A US 5589475 A US 5633238 A US 5336675 A AU 658424 B CA 2108880 A WO 9220327 A EP 0515301 A EP 0584185 A JP 6507617 T NO 934104 A NZ 242744 A US 5312817 A	28-09-1995 30-12-1992 30-12-1992 15-11-1992 15-11-1992 26-11-1992 02-03-1994 25-11-1998 01-09-1994 12-11-1993 24-02-1997 31-12-1996 27-05-1997 09-08-1994 13-04-1995 15-11-1992 26-11-1992 25-11-1992 02-03-1994 01-09-1994 12-11-1993 24-02-1997 17-05-1994
WO 9220328	A	26-11-1992	AU 663086 B AU 1873692 A AU 1886392 A CA 2062094 A CA 2103022 A EP 0515302 A EP 0584285 A EP 0879596 A JP 6507621 T NO 934103 A NZ 242743 A US 5589475 A US 5633238 A US 5336675 A AU 658424 B CA 2108880 A WO 9220327 A EP 0515301 A EP 0584185 A JP 6507617 T NO 934104 A NZ 242744 A US 5312817 A	28-09-1995 30-12-1992 30-12-1992 15-11-1992 15-11-1992 25-11-1992 02-03-1994 25-11-1998 01-09-1994 12-11-1993 24-02-1997 31-12-1996 27-05-1997 09-08-1994 13-04-1995 15-11-1992 26-11-1992 25-11-1992 02-03-1994 01-09-1994 12-11-1993 24-02-1997 17-05-1994
US 4550113	A	29-10-1985	NONE	
WO 9529909	A	09-11-1995	AU 1884595 A	29-11-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02378

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9529909 A		CA 2188427 A	09-11-1995
		EP 0757685 A	12-02-1997
		FI 964340 A	28-10-1996
		JP 9506371 T	24-06-1997
EP 0229391 A	22-07-1987	AU 6690686 A	02-07-1987
		CA 1279317 A	22-01-1991
		DE 3686248 A	03-09-1992
		DK 623586 A	28-06-1987
		ES 2044836 T	16-01-1994
		GR 3005315 T	24-05-1993
		JP 2716965 B	18-02-1998
		JP 8333255 A	17-12-1996
		JP 2597559 B	09-04-1997
		JP 62234065 A	14-10-1987
		US 5424318 A	13-06-1995
		US 4942169 A	17-07-1990
		US 5654306 A	05-08-1997
		US 5039681 A	13-08-1991
		US 5118684 A	02-06-1992
		US 5306720 A	26-04-1994
		US 4849431 A	18-07-1989
EP 0411534 A	06-02-1991	US 4999430 A	12-03-1991
		AT 119885 T	15-04-1995
		AU 5994590 A	31-01-1991
		CA 2022297 A	01-02-1991
		DE 69017789 D	20-04-1995
		DE 69017789 T	13-07-1995
		DK 411534 T	24-07-1995
		EP 0628548 A	14-12-1994
		ES 2068955 T	01-05-1995
		IE 66823 B	07-02-1996
		JP 3066670 A	22-03-1991
		PT 94849 A	18-04-1991
EP 0607864 A	27-07-1994	AU 670981 B	08-08-1996
		AU 5386194 A	21-07-1994
		CA 2113603 A	19-07-1994
		CN 1104211 A	28-06-1995
		FI 940229 A	21-10-1994
		HU 66182 A	28-09-1994
		JP 7206854 A	08-08-1995
		NO 940163 A	19-07-1994
		NZ 250682 A	21-12-1995
		US 5527800 A	18-06-1996
		US 5686466 A	11-11-1997
		ZA 9400203 A	12-07-1995
EP 0193926 A	10-09-1986	AU 595504 B	05-04-1990
		AU 5428486 A	11-09-1986
		CA 1284501 A	28-05-1991
		CY 1748 A	03-06-1994
		DK 99186 A	06-09-1986
		FI 860914 A,B	06-09-1986
		GR 860586 A	07-07-1986
		HK 130293 A	03-12-1993
		IE 58838 B	17-11-1993

INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/GB 98/02378

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0193926 A		JP 1629293 C	20-12-1991
		JP 2055416 B	27-11-1990
		JP 61225158 A	06-10-1986
		KR 9410764 B	11-11-1994
		PT 82127 B	01-07-1988
		SG 120793 G	14-10-1994
		US 4948807 A	14-08-1990
<hr/>			